New diabetes pill HRS9531 enters Mid-Stage trial – could it help control blood sugar?

NCT ID NCT07599410

Recruiting now Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This Phase 2 trial tests whether HRS9531 tablets can improve blood sugar control in people with type 2 diabetes who haven't achieved good control with lifestyle changes or metformin alone. About 240 participants will receive either the drug or a placebo for 20 weeks. The main goal is to see if HRS9531 lowers HbA1c levels, a key measure of long-term blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS9531 tablet
What this could lead to: If it works, this could offer a new daily pill to help people with type 2 diabetes better control their blood sugar and possibly lose weight.
What could go wrong: This is an early Phase 2 trial with only 240 people, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects like low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T2DM

Contacts and locations

Locations

Beijing Chaoyang Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100020, China
Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, 250012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.